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1. GENERAL FEATURE OF HUMAN INTESTINAL MI-
CROBIOTA
Human are borne in a practically germ-free state. Shortly after,
various microorganisms derived from the mother or environment
start to settle in many places of the body. Bacterial colonization
of the intestine is essential for its proper development and health.
The relationship between intestinal bacteria and health was real-
ized with the establishment of anaerobic culture methods and germ-
free breeding systems. Studies with axenic animals demonstrate
that colonizing microorganisms stimulate the maturation of intes-
tinal tissue, host metabolism, and absorption of nutrients, and
they fortify host protection systems such as mucus production
and secretory IgA (1). The effects of colonization are particularly
strong in the intestinal tract, where many kinds of bacteria live and
the total amount outnumbers host cells. A recent review by Rajili´c -
Stojanovi´c and de Vos (2) compiled the characteristics of more than
1000 species of microorganisms common to the human intestine.
Escherichia coli and Enterococcus are first detected just after birth ;
exposure probably occurs in the birth canal and the immediate
environment. During nursing, Bifidobacterium and Lactobacillus
become dominant. After weaning, various kinds of bacteria have
colonized the intestine and volume and diversity of microbiota in-
creased to the same level as in an adult. The relationship between
host and microbiota is symbiotic ; the host’s intestine provides a
place for bacteria to grow and supplies nutrition in the form of un-
digested food and removed mucus, while the bacteria ensure proper
tissue and immune development of the intestine as mentioned
above. These resident bacteria form a complex network that util-
izes various energy sources from the host or other bacteria to sur-
vive in the intestine. Growth, however, does not go unchecked. The
composition of intestinal microbiota is affected by many factors
including the host immune system, genetics, and environmental
elements. Thus, the proper functioning of host systems and the
microbiota is vital to intestinal homeostasis.
Comparing the differences in intestinal microbiota between
healthy and disease states or when diet, lifestyle, or disease con-
dition are altered clarifies the roles of intestinal bacteria in human
health. The intestinal bacterial population is complex, and identi-
fication of some species is difficult since they cannot be cultured.
Recent advances in sequencing techniques have improved the
ability to analyze the microbiota composition.
2. ANALYTICAL METHODS USED TO STUDY THE IN-
TESTINAL MICROBIOTA
In combination with germfree breeding system, development
of anaerobic culture technique have exceedingly contributed to
clarify the roles of intestinal bacteria in human health. Constantly
advancing technique for DNA sequencing has made analysis of in-
testinal microbiota more easily within shorter period. Now we will
be able to study intensively about how difference of bacterial com-
position influence the pathogenesis of life -style related pluricausal
diseases, why a population of bacteria increased under the patho-
genic state, what kind of intervention will improve the patient’s
condition. Characteristics of analytical methods used for intestinal
bacteria are described below. Combination of adequate method is
important for deeply understanding the role of intestinal bacteria.
Culture method
In the method of Mitsuoka et al. (3), diluted fecal samples were
spread onto nonselective (e.g. BL agar, EG agar) and selective
media (e.g. Rogosa SL agar, DHL agar), and then were cultured
under aerobic or anaerobic conditions. Physical features of the
colonies, Gram staining, and biochemical properties of the isolates
were used to determine their genus or species. The viable number
of identified bacteria were then calculated. Culture methods for
analysis of intestinal bacteria are difficult for several reasons. For
one, an expert is usually required to discriminate between colonies.
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In addition, growth of bacteria is influenced by many factors includ-
ing the constitution of the media or the manner in which the cul-
tures were pretreated. Despite the difficulties, a small number of
bacteria in the intestine can be discovered with the appropriate
selective media. Isolated bacteria are then placed in a gnotobiotic
animal model to investigate its functions. For strict anaerobes that
are very difficult to culture (e.g. extremely-oxygen sensitive Clos-
tridium), a whole fecal sample treated with chloroform was inocu-
lated into a germ-free animal intestine as described by Momose
et al. (4)
Culture-independent methods
Almost culture- independent methods target 16S ribosomal RNA
gene (16S rDNA), which is common among prokaryote and con-
sisted from highly conserved and variable regions. Conserved re-
gions are utilized as primer binding site in amplification or sequenc-
ing of this gene, and difference of DNA sequence in variable regions
are important for discrimination of genus or species of bacteria. Re-
cently advancing metagenomic analysis targets 16S rDNA or whole
genome in the samples. Anyway, complete extraction of bacterial
DNA from samples is important for precise analysis. Physical destruc-
tion with glass beads, enzymatic hydrolysis (5) or benzyl chloride
(6) were used to destroy the bacterial cell wall. We extracted DNA
from fecal samples by the method of Morita et al. (5). Briefly, fecal
samples were washed with a solution of 10 mM Tris-HCl and 50 mM
EDTA (pH 8.0) to remove PCR inhibitors such as bile acid and some
food-derived components, and were treated with achromopeptidase,
lysozyme and proteinase, and finally with SDS for complete lysis.
Complete lysis of bacteria was confirmed by Gram staining.
Among 16S rDNA-targeting methods, terminal -restriction frag-
ment length polymorphism (T-RFLP) analysis is good at finding
time-dependent changes or the effect of some food components
on an individual’s microbiota. In our previous studies, intestinal
microbiota was analyzed according to the method of Sakamoto et
al. (7). The procedure is outlined in Figure 1 and used primers are
shown in Table 1. The bacterial 16S rDNA was amplified by PCR
using 5’ -6 -carboxyfluorescein (6-FAM) -labeled 27F primer and
1492R primer except for Bifidobacterium (7). Then, PCR products
were digested with restriction enzymes HhaI and MspI, and 5’ -
labeled restriction fragments were examined in a genetic analyzer.
Polymorphisms of the fragments reflect the constituents of intes-
tinal microbiota. The sizes of 5’ - labeled restriction fragments vary
due to the genus- or species-dependent difference of digestion pat-
terns, so the unique size of the fragments aid in identification.
Although the exact species of changing bacteria cannot be deter-
mined, it can be supposed from the size of the T-RF peak by com-
puter simulation with a phylogenetic assignment database for T-
RFLP analysis of human colonic microbiota as described by Jin et
al. (8) and Matsumoto et al. (9), or by Microbiota Profiler software
(Infocom, Tokyo, Japan). By clustering the T-RFLP profiles and
combining them with individual information such as dietary habits
and disease states, we can consider which bacterial change has an
important effect on healthy or disease conditions. Because of easy
operation and comparative inexpensiveness, T-RFLP is suitable for
screening out changes or differences of microbiota composition.
But PCR bias is the inevitable problem due to fidelity of primers or
efficiency of amplification. Nagashima et al. (10) proposed new
primer-enzyme combinations to T-RFLP profiling of bacterial popu-
lations. They amplified 16S rDNA with using fluorescently labeled
516f primer and 1510r primer and then digested with RsaI plus BfaI
or with BslI. They mentioned that this new protocol made it easy to
predict what kind of intestinal bacterial group corresponded to each
T-RF including Bifidobacterium.
To determine the amount of targeted bacteria correctly, genus-
or species-specific real - time PCR is a powerful method. We con-
firmed the results of T-RFLP by genus-specific real - time PCR with
primers in Table 1. By using cloned 16S rDNA prepared from stan-
dard strains, we determined the copy number of the 16S rRNA gene
Figure 1. Outline for analysis of intestinal microbiota by Terminal -RFLP.
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from several bacteria (16, 17). Recently, a new quantification sys-
tem based on reverse transcription-quantitative PCR targeting of
multicopy rRNA molecules was established by Matsuda et al. (18).
They demonstrated the precise detection of subdominant popu-
lations such as Staphylococcus and Pseudomonas or those only de-
tected at lower incidences by quantitative PCR and culture methods.
16S rDNA-targeting clone library method was used for phylo-
genetic analysis of complex microbiota including unknown bacte-
ria (19, 20). 16S rDNA was amplified by PCR with lower cycles to
reproduce the original composition of microbiota, and PCR products
were cloned and used for sequencing. Clustering of the 16S se-
quences into phylum group and the frequency of the clones in
each phylum group entirely described the composition of micro-
biota. Representative 16S sequence in each group is used for ho-
mology search to identify the bacteria. More complicated steps,
longer time and more cost were needed compared to T-RFLP or
other methods. However, recent advances in sequencing technol-
ogy have resolved this problem.
Next generation sequencer can do large-scale sequencing ac-
curately and reproducibly. It contributes to rapid analysis of com-
plex intestinal microbiota. As summarized by Yamada (21), 16S
rDNA-targeting metagenome analysis is very helpful to know the
difference of complicated microbiota phylogenetically. In a gen-
eral metagenomics analysis, DNA fragments from whole genome
are directly sequenced. Enormous sequence data is assembled
into contig, and compared with sequences in common databases
to assign their functions. By comparing the composition of func-
tional genes between healthy and diseased state, we can know
which function of intestinal microbiota have a key role in mainte-
nance of health or in the pathogenesis of many kinds of disease,
although a high degree of data processing technique with more
time and cost are needed for this method.
Fluorescence in situ hybridization (FISH) can visualize the be-
havior of intestinal bacteria in the intestinal environment with
keeping the tissue structure. Since intestinal bacteria contain fairly
large amount of rRNA, genus- or population-specific probes for 16S
rRNA have been developed to examine their spatial distribution
(22). If we will use multiple probe labeled with different fluorescent
dyes, we can find an abnormality of bacteria’s location and changes
of bacterial composition. Intestinal bacteria was perfectly separated
from epithelium by secreted mucus in the healthy condition, but
penetration of bacteria into the mucus layer have been observed
in experimental models and in patients with inflammatory bowel
diseases (23, 24).
Analysis of metabolites produced by intestinal microbiota
Intestinal microbiota affects human health directly or indirectly
through their metabolites. Bacteria present in the lower intestinal
tract metabolize indigestible dietary fiber and mucus components
into short chain fatty acids (SCFA) such as propionic acid and bu-
tyric acid. These organic acids are absorbed into the colonic epi-
thelium where they are used for many purposes, including : being
used as an energy source, stimulating growth, differentiation, and
mucin production of epithelial cells, fortifying intestinal barrier
functions, and regulating the immune response (25, 26). SCFA
also functions as modulator in fatty acid metabolism by stimulating
secretion of GLP-1 and peptide YY, and in energy expenditure
through enteric nervous system (27). The other absorbable me-
tabolites have been associated with systemic diseases. Trimethyl-
amine (TMA) produced by intestinal bacteria from dietary choline
and L-carnitine, was further metabolized to trimethylamine-N -
oxide (TMAO) and promoted atherosclerosis (28). Hsiao et al. (29)
demonstrated through serum metabolome analysis that 4-eth-
ylphenylsulfate, a uremic toxin produced by intestinal bacteria, was
absorbed under dysbiotic condition and involved in the autism.
3. EFFECTS OF A FIBER-RICH FERMENTED FOOD
ON THE RAT INTESTINAL MICROBIOTA
We analyzed the effect of fermented brown rice (FBRA), which
is rich in dietary fiber, on the rat intestinal microbiota. Among
cultured bacteria, Lactobacillus significantly increased in the 10%
FBRA-fed group compared to the basal diet - fed group. T-RFLP
analysis also showed that FBRA substantially affected the intestinal
microbiota (30). The T-RF peak corresponding to the Lactobacillus
genus significantly increased with 10% FBRA feeding, and the frag-
ment size of the T-RF peaks suggested an increase of Lactobacillus
Table 1 Primers used for T-RFLP and quantitative PCR
Assay/object Primer Sequence Reference
T-RFLP
27F-FAM 6FAM-AGAGTTTGATCCTGGCTCAG
7
1492R GGTTACCTTGTTACGACTT
Bifidobacterium
Bif164F CATCCGGCATTACCACCC
11
Bif662R CCACCGTTACACCGGGAA
Sulfate -reducing
bacteria
Des- f CCGTAGATATCTGGAGGAACATCAG
12
Des-r ACATCTAGCATCCATCGTTTACAGC
Enterococcus
Enc-F CCCTTATTGTTAGTTGCCATCATT
13
Enc-R ACTCGTTGTACTTCCCATTGT
Clostridium
subcluster I
CI -F1 TACCHRAGGAGGAAGCCAC
14
CI-R2 GTTCTTCCTAATCTCTACGCAT
Clostridium
subcluster XI
CXI-F1 ACGCTACTTGAGGAGGA
CXI-R2 GAGCCGTAGCCTTTCACT
Clostridium
subcluster XIVab
CXIV-F1 GAWGAAGTATYTCGGTATGT
CXIV-R2 CTACGCWCCCTTTACAC
Clostridium
common probe Clostridium probe 6FAM-GTGCCAGCAGCCGCGGTAATACG-TAMRA
Bacteroides
AllBac296F GAGAGGAAGGTCCCCAC
15AllBac412R CGCTACTTGGCTGGTTCAG
AllBac375Probe 6FAM-CCATTGACCAATATTCCTCACTGCTGCCT-TAMRA
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acidophilus, L. johnsonii, and L. intestinalis species (Figure 2a).
T-RFLP profiles of fecal microbiota in the 10% FBRA-fed group
showed a different cluster from the basal diet - fed group (Figure
2b). Some lactic acid bacteria were isolated directly from the FBRA
itself, but they were not the same species as those isolated from
rat intestine as shown by randomly amplified polymorphic DNA
(RAPD) analysis. These results indicate that addition of FBRA to
the rat diet increases the resident Lactobacillus in the intestine.
Dextran sulfate sodium (DSS) treatment of rats induces colitis
with similar histological features to human ulcerative colitis (31).
We showed that addition of FBRA to the diet had an inhibitory
effect on formation of ulcers in the rat DSS-induced colitis model.
Myeloperoxidase activity in colonic mucosa, a marker of neutro-
phil infiltration, also significantly decreased in the 10% FBRA-fed
rats. DSS treatment caused a decrease in fecal Lactobacillus, but
the decrease was suppressed in FBRA-fed rats (32).
How Lactobacillus correlates with the suppression of colitis was
not further studied in this work, but some strains of Lactobacillus
have been reported to fortify intestinal barrier functions and to
regulate excess immune response by inducing regulatory T cells
(33, 34). FBRA contains a large amount of two types of dietary fiber,
β -glucan and arabinoxylan, which can be used as a carbon source
Figure 2. Rat fecal microbiota analyzed by Terminal -RFLP. Representative T-RFLP profiles (a) and dendrogram analysis (b) of rats fed a basal
or FBRA-containing diet. (Cited from reference number 30)
30 K. Kataoka Intestinal microbiota and human health
by Lactobacillus and could help to maintain a beneficial number of
the bacteria in DSS-treated rats. Lactic acid produced by Lacto-
bacillus is further metabolized to SCFA, such as butyric acid, by
metabolic cross- feeding among many kinds of intestinal bacteria.
Members of Negativicutes such as Veillonella and Megasphaera,
which are gram-negative staining and abundant in gastrointesti-
nal tract, utilize lactic acid and acetic acid to produce SCFA (2).
Bacteria-derived organic acids have been shown to induce anti -
inflammatory effects and intestinal barrier fortification (26).
4. EFFECTS OF A FIBER-RICH FERMENTED FOOD
ON THE HUMAN FECAL MICROBIOTA
Based on the increased number of resident Lactobacillus in rats
(30) and the suppressive effect in the DSS-induced colitis model
(32), we planned to estimate beneficial effects of FBRA in human
by randomized placebo-controlled crossover trial. In the first study,
effects of FBRA on the fecal microbiota and bowel function in healthy
adults were examined (16). While FBRA supplied the Ministry of
Health, Labour and Welfare, Japan’s recommended daily intake
of fiber, no significant effects on the intestinal microbiota compo-
sition and organic acids concentration were found after ingestion
of FBRA for 2 weeks. This was in contrast to in vitro results ; ad-
dition of FBRA to fresh fecal samples showed increase of organic
acids (SCFAs) and T-RF peaks that corresponded to Clostridium
subcluster XIVab and Bifidobacterium. Probably human adults have
very stable intestinal microbiota and is not easily influenced by
the dose and ingestion period used in this study.
In another study to estimate the effectiveness of FBRA in UC
patients under leadership of Dr. Hideki Ishikawa (Kyoto Prefec-
tural University), we covered to examine the change of fecal micro-
biota. Subjects ingested 21 g of FBRA or control food per day (the
same dose as in the healthy adults) for 3 months. Before and after
the first -eating period T-RFLP profile of fecal microbiota and bac-
terial metabolites showed no significant difference (unpublished
data), while fecal microbiota of UC patients before the intervention
was different from that of healthy adults as described in section 5.
Many clinical trials for UC patients showed beneficial effects of
probiotics (35, 36), and recently VSL#3 has been demonstrated to
be effective in maintenance/induction of remission and decrease
of clinical disease activity in large-scale, randomized, double-blind,
placebo-controlled trial (37). Synbiotics consisted from Bifidobac-
terium breve and galacto-oligosaccharide (38) or Bifidobacterium
longum and psyllium (39) also ameliorated colitis or patient’s quality -
of - life. However, only a few clinical trials have suggested beneficial
effects of prebiotics in UC patients. Oligofructose-enriched inulin
(12 g/day for 2 weeks) was tested in a randomized, placebo-con-
trolled, double-blind pilot trial (35, 40). Intestinal inflammation
evaluated with a fecal concentration of calprotectin was reduced
significantly at the middle point only in the group receiving oli-
gofructose-enriched inulin. But at the end of the study period,
disease activity scores were significantly reduced in both group.
Germinated barley foodstuff (GBF) is a dietary component high
in glutamine-rich protein and hemi-cellulose-rich dietary fiber,
and showed suppressive effect in experimental colitis and patients
with UC (35, 41-45). In small -scale multi -center open trial, patients
treated with 20-30 g of GBF for 24 week showed significant de-
crease in clinical activity index (CAI) (41). Randomized controlled
trials also showed decrease of CAI and prolonged remission period
by 20 g of GBF for 12 months (42), reduced level of serum TNF-α,
IL-6, IL-8 and serum CRP level by 30 g of GBF for 2 months (43,
44). However, a large, double-blind, placebo-controlled trial is not
yet reported.
Verification of prebiotic potential in human may probably need
an adequate dose and ingestion period for individuals. In the above
clinical trials with GBF, considerable doses of GBF were used for
longer period. Enhanced luminal butyrate production by GBF treat-
ment (45) might improve the patient’s symptoms, and high water-
holding capacity of GBF itself could contribute the amelioration.
If a functional component which can improve intestinal environ-
ment was contained, like as GBF-mediated regulation of the fecal
water content, effects of prebiotics might appear more clearly. Since
human intestinal microbiota has individually different composition
even at the start of clinical trials, growth of beneficial bacteria is
stimulated by prebiotics to various degrees. Efficiency of metabolic
cross- feeding between intestinal bacteria also affect the constitu-
tion of SCFA in the intestine. Time-, diet - and disease-dependent
change of bacterial composition could possibly interfere the action
of prebiotics and concentration of effective metabolites. We com-
pared bacterial composition and SCFA concentrations in feces in
healthy adults before and after experimental food, in vivo effects
were difficult to detect due to the large inter - individual variation.
In UC patients, disease state (remission or clinically active) influ-
enced the concentration of SCFA. Reduced diversity of intestinal
microbiota in UC patients (described in section 5) may also be re-
lated to indistinct results in the trials.
5. COMPARATIVE ANALYSIS OF THE FECAL MICRO-
BIOTA BETWEEN HEALTHY ADULTS AND PATIENTS
WITH ULCERATIVE COLITIS
The healthy gut environment is controlled by a complicated bal-
ance of the intestinal microbiota, their metabolites, and the host im-
mune system. Imbalance of these factors can promote disease
states like inflammatory bowel disease. Since the two clinical stud-
ies described above were run at the same time, we compared the
microbiota in UC patients before experimental food with those in
healthy adults and found a reduced diversity and imbalance of fecal
microbiota in UC patients (17). The total number of T-RF peaks
was significantly lower in patients in remission than in healthy
adults. Clustering analysis of T-RFLP profiles indicated that UC
patient’s microbiota formed different clusters from those of healthy
subjects without dependence on disease activity (Figure 3b). T-
RFLP analyses in UC patients showed decreasing peak area which
corresponded to Clostridium and Bacteroides (Figure 3a). Decrease
of genus Bacteroides and Clostridium subcluster XIVab was con-
firmed by genus- or species-specific real - time PCR (Figure 4a).
Probably due to the decrease of these dominant anaerobes, we ob-
served an increase of Enterococcus by culture and real - time PCR
in UC patients. Medical treatment and intake of probiotics did not
affect the differences in the microbiota between healthy and UC
subjects.
Bacteroides and Clostridium subcluster XIVab belong to the domi-
nant phyla Bacteroidetes and Firmicutes in the human intestinal
microbiota, and they cooperatively ferment undigested food com-
ponents to SCFAs by metabolic cross- feeding (46-48). Consistent
with the reduction of these anaerobes, there was a lower concen-
tration of fecal organic acids in UC patients compared to healthy
adults (Figure 4b). These results indicate that dysbiosis occurred
in UC patients. Similar features have been reported for intestinal
microbiota in UC and Crohn’s disease patients (49-51). Andoh et
al. (49) showed the altered T-RFLP patterns in UC patients. Some
T-RFs, derived from the unclassified bacteria, Ruminococcus, Eub-
acterium, Fusobacterium, gammaproteobacteria, unclassified Bac-
teroides, and unclassified Lactobacillus were detected in the UC
patients, but not in the healthy individuals. Such difference was
also found between the active UC patients and remission patients.
Nishikawa et al. (50) compared the mucosa-associated microbiota
between UC patients and non- inflammatory bowel disease (IBD)
controls by T-RFLP analysis. They showed that active UC patients
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Figure 3. Comparison of intestinal microbiota between healthy adults and patients with ulcerative colitis. Representative T-RFLP profiles (a) and
dendrogram analysis (b) of fecal microbiota in healthy control and UC patients. (Cited from reference number 16 and 17, and revised)
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possessed significantly fewer diverse microbial compositions, but
increased diversity of microbiota was observed in remission phase
of identical patients. Reduced diversity of faecal microbiota in
Crohn’s disease (CD) was revealed by Manichanh et al. (51). They
compared two DNA libraries constructed from faecal samples from
heathy donors and patients with CD, and identified 125 non-redun-
dant ribotypes, mainly represented by the phyla Bacteroidetes and
Firmicutes. Number of distinct ribotypes belonging to Firmicutes
was less in library from CD patients than that from healthy donor.
Significant reduction of this phylum was confirmed by fluorescent
in situ hybridization directly targeting 16S rRNA in faecal samples.
In this study, we compared fecal microbiota at only one time point ;
however, the intestinal microbiota has been reported to be unsta-
ble and easily changed during clinical remission (52). Therefore,
further investigation of samples from UC patients at different stages
of remission and of samples from different sites are required to con-
firm the microbiota differences between UC patients and healthy
individuals seen in this study.
6. CHANGES OF THE INTESTINAL MICROBIOTA IN
CHRONIC INFLAMMATORY BOWEL DISEASES AND
LIFESTYLE-RELATED DISEASES
The intestinal tract is an important organ for absorption of nutri-
ents, and it functions as a physical and biochemical barrier against
food-derived antigens and pathogenic microorganisms. Develop-
ment of these protective functions is stimulated by colonization
of commensal bacteria. Closely crowded commensal bacteria in
the lumen or on the surface of intestinal mucosa competitively
prevent growth of pathogenic bacteria of foreign origin (53). En-
hanced production of mucin, antibacterial peptides, and secretory
IgA associated with commensal bacteria in the intestine has also
been reported (1, 25, 53, 54). These resident bacteria also contrib-
uted to the enhancing effect through their colonization and their
metabolite organic acids (25, 26). Balanced microbiota is neces-
sary for producing organic acids with adequate amount and pro-
portion because of metabolic cross- feeding among anaerobic in-
testinal bacteria (46-48). Colonization of some commensals, such
as Bacteroides and Bifidobacterium, has been reported to fortify the
intestinal barrier by stimulating expression of antibacterial sub-
stances and intercellular adhesion molecules, and to suppress in-
flammation by modulating transduction of inflammatory signals or
by inducing regulatory T cells (Treg cells) (34). Clostridium has
also been demonstrated to suppress an excessive immune response
by induction of Treg cells, in part through the fermentation me-
tabolite butyrate (55, 56).
As summarized in Figure 5, colonized bacteria stimulate the
maturation of the human intestine and form a symbiotic relation-
ship through interaction with host defense systems. The human
host provides a place and nutrients for the microbiota to grow while
maintaining an adequate distance from the microbiota through
innate immune mechanisms. When this exquisite balance is col-
lapsed, the host immune cells attack resident bacteria ; persons
with certain genetic deficiencies in regulation of the immune re-
sponse may experience chronic intestinal inflammation when this
occurs.
Chronic intestinal disease may be caused by a mixture of defects
of immune response genes of the host and environmental factors.
Pathogenesis of Crohn’s disease, a chronic inflammatory bowel
Figure 4. Decrease of dominant anaerobes and their fermentative metabolites in UC patients. Quantitative PCR for Bacteroides and Clostridium
subcluster XIVab (a) and fecal concentration of organic acids (b) are shown. *Significant difference from healthy control (p0.05, Mann-Whitney
U - test). (Cited from reference number 16 and 17, and revised)
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disease (IBD), includes genetic deficiency in pathogen sensor mole-
cules such as NOD2 and TLR5 and autophagy gene (57-59). In
ulcerative colitis, the protective mucosal layer of the colon is lost
because mucin-producing goblet cells are reduced ; however, the
genetic causes have not yet been clarified. NOD2 is a sensor for
intracellular microorganisms. TLR5 recognizes flagellin of pene-
trating bacteria, and it sends signals to induce production of anti-
bacterial peptides and sIgA. Atg16L1 is responsible for the genera-
tion of autophagosome, and plays an important role in degradation
of intracellular bacteria, and in regulating the secretion of proin-
flammatory cytokines (58, 60).
Defects in these molecules reduce certain protective functions
in the intestine that maintain the distance between host and com-
mensal bacteria, resulting in an immune response to resident bac-
teria. In addition to genetic vulnerability, environmental factors
such as overwork, stress, and infection may trigger these intestinal
diseases. These factors cumulatively cause a collapse of the sym-
biotic relationship, at which point the host immune system attacks
the intestinal commensal bacteria. Chronic colitis is thought to
be the result of a combination of continuous inflammation against
commensal bacteria, lowered regulation of the immune response,
and reduced tissue repair activity. Decrease of dominant bacteria
and less diversity in intestinal microbiota are now considered com-
mon features of IBD. Restoration of balance of the intestinal mi-
crobiota may be one of the only effective treatments for patients.
Recently, bacterial transplantation has been demonstrated to be
effective in patients with UC (61) and in colitis caused by repeated
antibiotic treatments for Clostridium difficile infection (62).
Changed intestinal microbiota and dysbiosis are also correlated
with lifestyle -related diseases. A markedly reduced diversity and
compositional change of the gut microbiota has been linked to obe-
sity and insulin resistance (63-65). A high fat diet was shown to
affect the composition of gut microbiota through modifying the
expression of bacterial genes responsible for nutrient uptake and
adaptation to environmental change in the host intestine (66). A
dysbiotic intestinal environment contributes to the pathogenesis
of liver diseases (67, 68). Also, Schnabl and Brenner (68) showed
a correlation between altered intestinal microbiota and nonalco-
holic fatty liver disease/steatohepatitis. Furthermore, absorbed
bacterial metabolites have the potential to systemically enhance the
development of these metabolic diseases. Treatment with prebiotics
or probiotics has been reported to reverse high fat diet - induced
metabolic disorders through an increase of Akkermansia muciniphila
(69) and to suppress nonalcoholic steatohepatitis (70) in a rodent
model.
7. CONCLUDING REMARKS
The lifestyle of the average person, especially in regards to die-
tary habits, has changed dramatically over the past several decades.
A parallel increase in patients with inflammatory bowel diseases,
irritable bowel disease, allergy, autoimmune diseases, and meta-
bolic diseases like type 2 diabetes and fatty liver disease has oc-
curred. The role of the intestinal microbiota in human health is
apparent now because of research that connects changes of the
gut microbiota with the risk of diseases. The diversity and total
amount of intestinal microbiota is continuously influenced by en-
vironmental bacteria, dietary habits, exercises, stress, aging, in-
take of probiotics/prebiotics, medical treatment with antibiotics or
other drugs, host immune system, and the person’s genetic back-
ground (63, 71). While modification of the intestinal microbiota
and intestinal environment including mucosal immune system could
affect the risk of many kinds of diseases, the strongest influence
might occur during early stage of life as described elsewhere (63,
72-74). Despite our understanding that the microbiota is a critical
part of health, it remains to be discovered what type of microbiota
should be present at different stages of life. Further studies should
focus on how to maintain a healthy composition of the intestinal
microbiota.
Although 16S rDNA-targeting PCR and sequencing analyses
yielded information about microbiota composition at the genus
or species level, variation between individuals was too large to find
a functional difference between healthy and disease states. Im-
provement of current sequencing techniques would allow better
analysis of the complexity of the gut microbiota. Alternatively, we
could look for a change in specific bacterial gene functions in dis-
eased persons. Large scale metagenomics studies of disease and
healthy states have begun to point to the kinds of bacteria that cor-
relate with risk of disease. The NIH “Human Microbiome Project”
has steadily been clarifying the relationship between intestinal mi-
crobiota and human health by this method (75). Recently, a different
Figure 5. The symbiotic relationship between the host and the intestinal microbiota contribute to human health.
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metagenome-wide association study reported taxonomic and func-
tional characterization of gut microbiota in type 2 diabetes, and
they correlated the disease with lack of bacterial richness and meta-
bolic markers (76, 77). Additionally, bacterial metabolites, which
are affected by dietary components, should be analyzed because
these products from dietary can affect human health similar to some
metabolic diseases. Careful studies to clarify the roles of intestinal
microbiota in human health will bring us great progress in treat-
ment and prevention of many kinds of diseases.
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